AbbVie’s case against the NHS thrown out of court

pharmafile | January 22, 2019 | News story | Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health 

A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court.

Mr Justice Choudhury, a judge at the Technology and Construction Court, dismissed AbbVie’s case against the NHS, after the US firm alleged that NHS England’s procurement process for curative drugs for Hepatitis C (HCV) was unfair.

The Judge rejected the arguments of the Illinois-based multinational, after the firm launched a legal challenge against NHS England’s £1 billion procurement of drugs for HCV.

The allegations came after NHS England launched an initiative aimed at eliminating HCV by 2025. In doing this, the public health body attempted to launch the biggest procurement process in the organisation’s history. However the process was stalled after AbbVie claimed it was unfair.

The firm claimed that NHS England had failed in its duty to treat bidders fairly. The procurement process was aimed at reducing the cost of curative HCV drugs from around £35,000 to £10,000, in return for three year supply contracts. The drugs cure the deadly disease after just a few weeks of treatment.  

NHS England estimates that 160,000 people are infected with HCV. Around half of those people are believed to be unaware of their condition.

 John Stewart, director of specialised commissioning at NHS England, commented: “Court cases such as this are a waste of NHS resources and taxpayers’ money, in this case resulting in an unavoidable delay in our efforts to tackle the threat of hepatitis C, which disproportionately affects some of the most vulnerable and marginalised people in society.

“We remain committed to driving best value to help eliminate hepatitis C in England by 2025 or sooner, and with this court case behind us we can now get on with the job.”

Louis Goss

Related Content

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics …

AbbVie to acquire ImmunoGen for approximately $10.1bn

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy …

Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap

Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement …

Latest content